Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1244954 | 0.99 | FTO (0.56) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL4142445 | 0.96 | MAPT (0.60) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL723679 | 0.87 | FTO (0.58) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL723680 | 0.87 | FTO (0.58) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL21194989 | 0.86 | FTO (0.70) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL9692970 | 0.82 | FTO (0.47) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL19128901 | 0.81 | KMT2A (0.74) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL10682750 | 0.81 | FTO (0.65) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL6649726 | 0.79 | FTO (0.72) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL5174468 | 0.79 | FTO (0.75) | FTOMAPTMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663399-B1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | GC BIOPHARMA CORP. (KR) | 2021-08-05 | — | — | US | disclosed |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | GC BIOPHARMA CORP. (KR) | 2021-07-29 | — | — | US | disclosed |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3663399-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190055534-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | OAKTREE FUND ADMINISTRATION, LLC | 2019-02-21 | — | — | US | disclosed |
| US-10160961-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| EP-2877487-B1 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180251745-A1 | Compositions and Methods for Modulating Hemostasis | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2018-09-06 | — | — | US | disclosed |
| EP-1948690-A4 | COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS | PHILADELPHIA CHILDREN HOSPITAL (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1948690-A2 | COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007059513-A2 | COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2005103290-A1 | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH ASPARTYL AMINOPEPTIDASE (DNPEP) | BAYER HEALTHCARE AG (DE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1007548-A4 | TSETSE THROMBIN INHIBITOR | UNIV YALE (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6229055-B1 | SYNTHESIS OF FLUORINATED RESORCINOL WHICH IS USEFUL IN THE PREPARATION OF FLUORINATED FLUORESCEIN AND RHODOL DYES SUITABLE FOR USE AS TRACERS, LABELS, OR INTERMEDIATES | MOLECULAR PROBES, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6162931-A | Fluorinated xanthene derivatives | MOLECULAR PROBES, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1007548-A1 | TSETSE THROMBIN INHIBITOR | Yale University (US) | 2000-06-14 | — | — | EP | disclosed |
| US-6036958-A | POLYPEPTIDES WITH AMINO ACID SEQUENCES | YALE UNIVERSITY (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1997043309-A1 | TSETSE THROMBIN INHIBITOR | YALE UNIVERSITY (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160961-B2 | Factor VII polypeptides that are modified and uses thereof | F7, F13B, HABP2 | FTO 4053/4885MAPT 4660/4885MEN1 1713/4885 |
| US-20190055534-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | F7, F13B, HABP2 | FTO 4024/4885MAPT 4647/4885MEN1 1694/4885 |
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | F13B, F9, F13A1 | FTO 2308/4885MAPT 3507/4885MEN1 2092/4885 |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | F9, F13B, F13A1 | FTO 2454/4885MAPT 4318/4885MEN1 2505/4885 |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | F7, F13B, HABP2 | FTO 4024/4885MAPT 4647/4885MEN1 1694/4885 |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | F9, F13B, F8 | FTO 2361/4885MAPT 4271/4885MEN1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.